NRC — NRC Health stock price, charts and financials

QT48NRC Health

NRC Health (NASDAQ: NRC) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
19.59
+0.09+0.46%
NRCQT48NRC Health·NASDAQ
19.59+0.46%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E78.36EPS (ttm)0.25Insider Own-Shs Outstand22.54MPerf Week-12.31%
Market Cap441.49MForward P/E17.65EPS next Y1.11Insider Trans0.03%Shs Float11.84MPerf Month-12.93%
Enterprise Value528.49MPEG5.29EPS next Q0.21Inst Own-Short Float4.40%Perf Quarter7.52%
Income6.00MP/S3.15EPS this Y252.00%Inst Trans-Short Ratio4.25Perf Half Y-10.55%
Sales140.00MP/B63.07EPS next Y26.14%ROA4.30%Short Interest520.82KPerf YTD4.37%
Book/sh0.31P/C147.18EPS next 5Y14.81%ROE48.46%52W High23.68 -17.27%Perf Year55.72%
Cash/sh0.13P/FCF20.32EPS past 3/5Y-25.74% -18.54%ROIC8.75%52W Low11.01 77.93%Perf 3Y-54.67%
Dividend Est.0.64 (3.27%)EV/EBITDA22.02Sales past 3/5Y-3.40% 0.59%Gross Margin66.79%Volatility9.12% 5.59%Perf 5Y-62.51%
Dividend TTM0.60 (3.06%)EV/Sales3.77EPS Y/Y TTM-75.96%Oper. Margin10.53%ATR (14)1.29Perf 10Y25.98%
Dividend Ex-DateSep 25, 2026Quick Ratio0.65Sales Y/Y TTM-2.10%Profit Margin4.18%RSI (14)43.33Recom2.00
Dividend Gr. 3/5Y-14.77% 19.88%Current Ratio0.65EPS Q/Q10.71%SMA20-6.76%Beta0.36Target Price-
Payout216.92%Debt/Eq5.64Sales Q/Q2.94%SMA50-3.99%Rel Volume1.15Prev Close19.50
Employees357LT Debt/Eq5.36EarningsOct 26SMA20010.90%Avg Volume124.50KPrice19.59
IPO DateMay 23, 2013Option/ShortYes / YesEPS/Sales Surpr.306.67% -Net Debt/EBITDA3.71Volume143,758Change0.46%
Latest News
Aug-03-26
Jul-29-26
Jul-28-26
Jul-24-26
Jul-23-26
Jun-22-26
Company

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue140137143149152148133128120
Cost of Goods Sold Incl. D&A476057565752494648
Gross Profit937786939596848272
Selling, General and Administrative Excl. Other625545474339343331
Research and Development
000000000
Other Operating Expense1606656766
Operating Income162335404750434335
Interest Expense453112222
Unusual Expense
Non-Operating Income (Expense)0001-30101
Net Income Before Taxes81833404349414135
Income Taxes36891111485
Consolidated Net Income61225313237373230
Net Income From Continuing Operations61225313237373230
Net Income61225313237373230
EPS (Recurring)0.260.521.051.261.281.471.481.301.11
EPS (Basic, Before Extraordinaries)0.260.521.051.261.281.471.481.301.11
EPS (Diluted)0.250.521.041.251.271.461.451.261.07
EBITDA243041464957514942
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio78.3636.1016.9631.6529.3728.4429.4852.3335.64
Price To Sales Ratio3.083.012.966.646.137.018.0412.888.58
Gross Margin66.4356.2060.1462.4262.5064.8663.1664.0660.00
Operating Margin11.4316.7924.4826.8530.9233.7832.3333.5929.17
Net Margin4.298.7617.4820.8121.0525.0027.8225.0025.00
Shares Outstanding222224252525252527
Market Capitalization4314134239899321,0381,0691,6491,030
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$24.47$20.78$17.09$13.41$9.72 Close Price0.00K24.54K49.08K73.62K98.16KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HARRISON SHANE REVP & Chief Financial OfficerFeb 17 '26Buy12.278,00098,1628,000Feb 19
Hays Michael D.ChairmanJan 05 '26Option Exercise15.239,145139,27820,154Jan 07
Hrdy HelenEVP & Chief Operating OfficerDec 15 '25Option Exercise15.2312,346188,030151,762Dec 17
Freeman Jordan NicoleChief Accounting OfficerJul 31 '25Buy12.9777110,000771Aug 04
BEANS PATRICK E10% OwnerMay 12 '25Buy13.592,50033,97435,003May 13
Hays Michael D.CEO & PresidentJan 02 '25Option Exercise13.1710,014131,88411,009Jan 06
NUNNELLY JOHN NDirectorMar 27 '24Option Exercise14.959,259138,42236,153Mar 29
Common Property Trust10% OwnerMar 01 '24Sale40.54598,65324,269,3933,854,284Mar 05
Amandla MK Trust10% OwnerJan 05 '24Sale40.202,614105,0923,831,362Jan 08
Amandla MK Trust10% OwnerJan 04 '24Sale41.224,600189,6173,833,976Jan 08
Common Property Trust10% OwnerJan 03 '24Sale41.53364,62515,142,8764,452,937Jan 05
Amandla MK Trust10% OwnerJan 03 '24Sale41.77120,1395,018,7593,838,576Jan 04
Hays Michael D.CEO & PresidentJan 02 '24Option Exercise18.802,90454,5952,904Jan 04
Amandla MK Trust10% OwnerJan 02 '24Sale40.31201,1008,106,2463,958,715Jan 04
Amandla MK Trust10% OwnerDec 14 '23Sale41.5960024,9544,159,815Dec 14
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.